HTGC : Portfolio

About Us

Benefits of Venture Debt Why Choose Hercules Our Products Our Philosophy Why Recommend Hercules

Our Portfolio

A-Z List Biotechnology Communications and Networking Consumer Related Electronics and Computer Hardware Medical Devices Semiconductors and Components Software Other Prior Investments

Our Team

Investment Team Operations Team Board of Directors

Investor Relations

Analyst Information Contacts Corporate Governance Dividends Earnings Releases E-Mail Subscription Event & Presentations Financial Fundamentals Stock Information Investor FAQs Investor Kit Management Major Shareholders SEC Filings

E-Mail Subscription

Online Newsroom

Hercules Company News Hercules in the News Portfolio News Newsletter

Current Opportunities Internships Analysts Associates Managing Directors

SBIC Home For a Second, Consecutive Year
Hercules Employees Donate
Time to Habitat for Humanity
more...

Biotechnology

Acceleron Pharma, Inc.

Aegerion Pharmaceuticals

Alexza Pharmaceuticals

Althea Technologies

Aveo Pharmaceuticals

Chroma Therapeutics

Dicerna Pharmaceuticals

Elixir Pharmaceuticals

EpiCept

Horizon Therapeutics

Inotek Pharmaceuticals

Kamada

Labcyte

LaboPharm

Memory Pharmaceuticals

Merrimack Pharmaceuticals

Neosil

NuGEN Technologies

Omrix Biopharmaceuticals

Panacos Pharmaceuticals

Paratek Pharmaceuticals

PolyMedix

Portola Pharmaceuticals

QuatRx Pharmaceuticals

Recoly

Sirtris Pharmaceuticals

Solace Pharmaceuticals

Transcept Pharmaceuticals

Acceleron Pharma, Inc.

149 Sidney Street

Cambridge, MA 02139

617.649.9200

www.acceleronpharma.com

Acceleron Pharma is a biopharmaceutical company developing therapeutics for metabolic and musculoskeletal diseases affecting millions of people. In the complex and rapidly evolving field of drug development, the depth of the team and the way they work together are two of the most critical success factors. We have a unique culture, team, and approach that is rapidly translating our ideas and assets into drugs that will make a big difference in patients' lives.

Acceleron Pharma, Inc. in the News

1/14/2010	Acceleron Pharma Announces Addition of Two Novel Programs to Development Pipeline at the 28th Annual JP Morgan Healthcare Conference
1/7/2010	Acceleron Pharma to Present at the 28th Annual J.P. Morgan Healthcare Conference
12/22/2009	Acceleron Pharma Expands Management Team with Two New Appointments
12/16/2009	Acceleron Pharma Reports $10.9M Financing
12/10/2009	Acceleron Pharma Invests in Bricks & Mortar When Virtual is In Vogue
12/8/2009	Acceleron Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at 51st ASH Meeting
12/3/2009	Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma
12/1/2009	Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting of the American Society of Hematology
11/4/2009	Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
9/15/2009	Acceleron to Present at the UBS Global Life Sciences Conference
9/10/2009	Acceleron to Participate at the Morgan Stanley 2009 Global Healthcare Unplugged Conference
9/10/2009	Acceleron Pharma�s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
9/2/2009	Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial
7/28/2009	Acceleron and Celgene Initiate Phase 2 Study of ACE-011 to Treat Chemotherapy-Induced Anemia
7/27/2009	StartUpHire Announces the 10 Fastest Growing Startups in Boston
6/10/2009	Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function
6/8/2009	Acceleron Pharma to Present at Two Upcoming Investor Conferences
5/16/2009	GlobeImmune sells rights to cancer drugs
5/14/2009	Colliers Meredith & Grew Represents Acceleron Pharma in 19,711-Square-Foot Laboratory Lease
4/14/2009	Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009
3/12/2009	Acceleron to Present at the Cowen and Company 29th Annual Health Care Conference
1/13/2009	Acceleron Introduces Breakthrough Program for Treatment of Anemia at the 27th Annual JP Morgan Healthcare Conference
1/6/2009	Acceleron to Present at the 27th Annual JP Morgan Healthcare Conference
11/3/2008	Acceleron to Present at the Oppenheimer 19th Annual Health Care Conference
10/24/2008	Acceleron to Present at the 7th Annual Biotechnology Industry Organization Investor Forum
9/22/2008	Acceleron Pharma Acknowledged For Positive Impact On Economic Development In Massachusetts
6/16/2008	Acceleron doubles its space in Cambridge
5/9/2008	Acceleron's Bone Formation Drug Found Effective in Preclinical Studies
3/19/2008	Acceleron Pharma Implements SilkRoad technology�s OpenHire
2/20/2008	Celgene strikes deal with Acceleron Pharma
1/23/2008	Acceleron wins $1M for bone cancer research
9/24/2007	Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
9/20/2007	Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
9/18/2007	Acceleron Appoints John Knopf to CEO Spot
7/31/2007	Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference
7/16/2007	Super-buff cattle may hold key to treating muscular diseases
5/14/2007	Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies
4/25/2007	Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program Management
3/29/2007	Acceleron taps manufacturing head
3/29/2007	Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing

Problems with the site? Email webmaster@htgc.com

To download the Adobe Reader for free, click on the following link.

*Historical, intraday and current end-of-day data provided
by eSignal. Intraday data is at least 20-minutes delayed.